Results from a pivotal trial of a new HIV therapy, show that PRO 140 is an effective, long-acting therapeutic for previously treated HIV-1 infected patients…
Gilead Sciences announced results from a Phase II study demonstrating that the experimental integrase strand transfer inhibitor bictegravir achieved high virologic response rates similar to ViiV Healthcare's integrase inhibitor Tivicay (dolutegravir) in t